Patient demographics and clinical characteristics (N = 101)
Characteristics . | Data . |
---|---|
Sex | |
Female | 42 (42) |
Male | 59 (58) |
Age, y | |
Mean | 67 |
Median | 69 |
Range | 36-86 |
Clinical subtype | |
Acute | 68 (67) |
Lymphoma | 18 (18) |
Unfavorable chronic | 10 (10) |
Favorable chronic | 2 (2) |
Smoldering | 3 (3) |
Previous systemic chemotherapy | |
No | 17 (17) |
Yes | 84 (83) |
ECOG PS | |
0 | 27 (27) |
1 | 46 (45) |
2 | 16 (16) |
3 | 9 (9) |
4 | 3 (3) |
Serum sIL-2R (U/mL) | |
Mean | 14 491 |
Median | 5 530 |
Range | 516-192 000 |
HTLV-1 load (copies/1000 PBMCs) | |
Mean | 505.4 |
Median | 382.1 |
Range | 0.5-3 093.7 |
Serum Ca, mg/dL*,† | |
Mean | 9.5 |
Median | 9.3 |
Range | 5.8-16.2 |
Serum Alb, g/dL† | |
Mean | 3.5 |
Median | 3.6 |
Range | 2.0-4.6 |
Characteristics . | Data . |
---|---|
Sex | |
Female | 42 (42) |
Male | 59 (58) |
Age, y | |
Mean | 67 |
Median | 69 |
Range | 36-86 |
Clinical subtype | |
Acute | 68 (67) |
Lymphoma | 18 (18) |
Unfavorable chronic | 10 (10) |
Favorable chronic | 2 (2) |
Smoldering | 3 (3) |
Previous systemic chemotherapy | |
No | 17 (17) |
Yes | 84 (83) |
ECOG PS | |
0 | 27 (27) |
1 | 46 (45) |
2 | 16 (16) |
3 | 9 (9) |
4 | 3 (3) |
Serum sIL-2R (U/mL) | |
Mean | 14 491 |
Median | 5 530 |
Range | 516-192 000 |
HTLV-1 load (copies/1000 PBMCs) | |
Mean | 505.4 |
Median | 382.1 |
Range | 0.5-3 093.7 |
Serum Ca, mg/dL*,† | |
Mean | 9.5 |
Median | 9.3 |
Range | 5.8-16.2 |
Serum Alb, g/dL† | |
Mean | 3.5 |
Median | 3.6 |
Range | 2.0-4.6 |
Unless otherwise noted, data are n (%).
Alb, albumin; Ca, calcium; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HTLV-1, human T-cell lymphotropic virus type 1; PBMC, peripheral blood mononuclear cell; sIL-2R, soluble interleukin-2 receptor.
When serum Alb level was <4.0 g/dL, serum Ca was adjusted by the concentration of serum Alb as follows: adjusted Ca level (mg/dL) = measured Ca level (mg/dL) + (4 − Alb level [g/dL]).
Data were missing for 3 patients.